Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSR411298 as adjunctive treatment for persistent cancer pain
NCT01439919Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Jan 2012
- Primary completion
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SSR411298 in cancer pain, sponsored by Sanofi. Started Jan 2012; status: terminated.
02
Drugs
SSR411298
03
Conditions
cancer pain
Beyond the preview
Go deeper on NCT01439919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01439919.